Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Financing Activities: 2015-2024

Historic Cash from Financing Activities for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $185.7 million.

  • Intellia Therapeutics' Cash from Financing Activities rose 39.74% to $114.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.0 million, marking a year-over-year decrease of 26.18%. This contributed to the annual value of $185.7 million for FY2024, which is 42.53% up from last year.
  • As of FY2024, Intellia Therapeutics' Cash from Financing Activities stood at $185.7 million, which was up 42.53% from $130.3 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Cash from Financing Activities registered a high of $736.7 million during FY2021, and its lowest value of $130.3 million during FY2023.
  • In the last 3 years, Intellia Therapeutics' Cash from Financing Activities had a median value of $185.7 million in 2024 and averaged $299.7 million.
  • In the last 5 years, Intellia Therapeutics' Cash from Financing Activities soared by 386.41% in 2020 and then slumped by 77.64% in 2023.
  • Over the past 5 years, Intellia Therapeutics' Cash from Financing Activities (Yearly) stood at $371.8 million in 2020, then spiked by 98.15% to $736.7 million in 2021, then dropped by 20.87% to $583.0 million in 2022, then plummeted by 77.64% to $130.3 million in 2023, then surged by 42.53% to $185.7 million in 2024.